Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer

This research study is for patients that have breast cancer that has been surgically removed but has features that past research has found could indicate a significant risk of recurrence.  The purpose of the study is to see if adding an investigational drug (bevacizumab) to the current standard chemotherapy (doxorubicin, cyclophosphamide, and paclitaxel) reduces the risk of recurrence compared to standard chemotherapy alone.